New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 18, 2013
07:27 EDTAMAGAMAG Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
Leerink upgraded AMAG Pharmaceuticals on expectations Feraheme sales estimates are now achievable and label expansion can drive upside. The firm raised its price target for shares to $19 from $17.
News For AMAG From The Last 14 Days
Check below for free stories on AMAG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
07:20 EDTAMAGAMAG Pharmaceuticals raises FY14 revenue view to $93M-$102M, consensus $93.78M
AMAG Pharmaceuticals sees U.S. Feraheme net product sales of $80M-$87M, revised upward from the company's previous estimate of $75M-$85M; revenue from MuGard, ex-U.S. Feraheme product sales, royalties and milestones of $13M-$15M; lowered cost of goods sold guidance to 13%-15% of Feraheme net product sales from the company's previous estimate of 14%-16%; Increased total operating expense guidance to $87M-$92M from the company's previous estimate of $80M-$85M resulting from increased: Research and development expenses of $21M-$23M; Selling, general and administrative expenses of $66M-$69M; increased net loss guidance to $12M-$14M from the company's previous estimate of $10M-$12M. Both estimates include approximately $11M of interest expense from the $200M convertible debt offering in February 2014; lowered ending cash and investments guidance to $388M-$393M from the company's previous estimate of $392M-$397M at December 31.
07:15 EDTAMAGAMAG Pharmaceuticals reports Q2 EPS (7c), consensus (9c)
Reports Q2 revenue $24.8M, consensus $23.35M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use